Why Breakthrough Science Isn’t a Strategy

Reclaiming the leadership conversation. The first of three parts: structured inquiry.

When a breakthrough venture loses its bearings, the corporate reflex is to hire consultants. A team of analysts arrives, studies the market, and departs, leaving behind a slide deck of formidable length. The impulse is understandable. It is also, more often than not, a mistake. Strategy is not an asset that can be purchased; it is a discipline that has to be practiced, and it has to be led from within.

That is why I advise leadership teams to plan their strategy with an executive coach rather than with a battalion of outside analysts. A good coach makes no pretense of knowing your science better than you do. The coach’s job is narrower and, in some ways, harder: to provoke the conversations your executive team has been avoiding, to question the assumptions no one has thought to question, and to draw out what the team already knows but has not yet said aloud.

This essay is the first of three on how pioneering ventures can build a strategy that is both rigorous and true to their values. It concerns the first phase of that work, which I call structured inquiry. The second will take up the discipline of narrowing many options to three priorities; the third, the operational architecture required to carry them out.

The Deep-Tech Dilemma

In biotechnology, advanced materials, and climate technology, brilliance is rarely in short supply. These companies employ scientists who untangle intricate biological puzzles and engineers who redesign thermodynamic systems so that heavy industry might one day stop warming the planet. Everyone in the building believes in the mission. The ethical commitment is not in doubt.

And yet many of these ventures stall at a predictable moment: when the science has to become a business.

This is often when the consultants are summoned. What they deliver tends to be encyclopedic—long on macroeconomic forecasts, short on the texture of daily operations. The binders go on a shelf. The trouble is not a lack of diligence. An outside party cannot manufacture conviction inside a company, and it is poorly placed to weigh the delicate trade-offs involved in inventing a market that does not yet exist. A strategy works only when the people who must carry it out are the people who built it.

Phase I: Structured Inquiry

Strategy begins with questions, not answers. In a field where the technical and regulatory ground can shift within a single quarter, a five-year road map drafted in advance is less a plan than a wish. A leadership team does better to step back and interrogate its own assumptions. Five questions do most of the work.

The first concerns the company’s defensible edge: what technical and commercial advantage does it hold that a competitor could not readily duplicate? The second concerns the immediate customer—not the market the company hopes to serve in a decade but the particular early adopter who will pay for the breakthrough now. The third asks what could upend the enterprise from outside: a shift in capital markets, a rival platform technology, or a new regulatory regime that renders the approach obsolete before it reaches scale. The fourth turns inward, to capability gaps, and asks where the company’s skills and structures fall short of its mission’s ambition.

The fifth question, about capital, is the one most often deferred, and it may matter most. How does each strategic path translate into money? In deep tech and the life sciences, this rarely means forecasting near-term revenue, which would be speculative at best. It means modelling, with real rigor, the monthly burn rate, the ways runway might be extended, and the milestones that will release each tranche of capital. A strategy without financial mechanics is not a strategy. It is a story.

None of these questions needs a pristine answer at this stage. The purpose of the inquiry is to expose the organization’s blind spots, to bring its unspoken biases into the open, and to generate a broad portfolio of strategic options, each anchored in financial reality.

A Cautionary Tale

I’ve seen what happens when this step is skipped. For some time I worked with the leadership team of a small life-sciences company, run as lean as a startup, and I was with them before, during, and after a review that changed its course. The company’s larger corporate backer had hired a major consulting firm to conduct a full organizational review. The recommendations that came back were built for a different market and a different way of working. The proposed culture and people practices didn’t suit the market the company actually competes in. The formal processes added an administrative load that no lean startup could carry. The priorities had little to do with how modern, agile teams of any size really work.

The people who would have to carry out the plan had almost no part in shaping it. Before the review, the team had momentum. Afterward, it stalled. Valued people began to leave. The milestone the company exists to reach is now at risk.

The consultants did not fail to ask questions; they buried the team in them, few of which bore on the company’s real situation. When its leaders pushed for the right questions, they were stonewalled, and the report cited their pushback as evidence of defensiveness. The one inquiry that mattered never took place.

From Dialogue to Commitment

This kind of inquiry needs a facilitator—an impartial outsider who can keep leaders on task, manage the dynamics of an executive team, and make sure that every function, from the laboratory to investor relations, is heard without hierarchy smothering candor.

Inquiry yields the raw material of strategy, but a long list of possibilities is only a beginning. The next essay in this series takes up what I consider the hardest test of leadership: the discipline of eliminating good options so that a company can concentrate on the few that matter most.

In the meantime, here is a question to put to your executive team. If you asked each member, today, to name your company’s single most defensible edge and the precise tranche of capital required to prove it, would you hear one answer, or five?

If your team is approaching its next inflection point and wants an objective framework for turning scientific promise into commercial momentum, I would welcome a conversation about how facilitated strategic coaching might help.

Previous
Previous

The Case for Doing Less